VU0405601
Based on 1 Customer Validation
VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.93%
- CAS 番号: 712325-30-9
- 分子式: C17H13BrN2O2
- 分子量:357.20
-
保管条件:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
生物活性
KV11.1[1]
VU0405601 (5 µM; pretreated for 30 min before 100 nm dofetilide) protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia[2].
VU0405601 (50 µM) can be used as a hERG agonist and increases test pulse and tail currents, increases the IC50 of dofetilide from 38.7 to 76.3 nm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 712325-30-9
-
性状 Solid
-
分子量 357.20
-
分子式 C17H13BrN2O2
-
Color White to off-white
-
SMILES
O=C(COC1=CC=C2C=CC=CC2=C1Br)NC3=CC=CN=C3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 100 mg/mL (279.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Egly CL, et al. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants. Mol Pharmacol. 2022 Apr;101(4):236-245. [Content Brief]
[2]. Potet F, et al. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. J Biol Chem. 2012 Nov 16;287(47):39613-25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7996 mL | 13.9978 mL | 27.9955 mL | 69.9888 mL |
| 5 mM | 0.5599 mL | 2.7996 mL | 5.5991 mL | 13.9978 mL | |
| 10 mM | 0.2800 mL | 1.3998 mL | 2.7996 mL | 6.9989 mL | |
| 15 mM | 0.1866 mL | 0.9332 mL | 1.8664 mL | 4.6659 mL | |
| 20 mM | 0.1400 mL | 0.6999 mL | 1.3998 mL | 3.4994 mL | |
| 25 mM | 0.1120 mL | 0.5599 mL | 1.1198 mL | 2.7996 mL | |
| 30 mM | 0.0933 mL | 0.4666 mL | 0.9332 mL | 2.3330 mL | |
| 40 mM | 0.0700 mL | 0.3499 mL | 0.6999 mL | 1.7497 mL | |
| 50 mM | 0.0560 mL | 0.2800 mL | 0.5599 mL | 1.3998 mL | |
| 60 mM | 0.0467 mL | 0.2333 mL | 0.4666 mL | 1.1665 mL | |
| 80 mM | 0.0350 mL | 0.1750 mL | 0.3499 mL | 0.8749 mL | |
| 100 mM | 0.0280 mL | 0.1400 mL | 0.2800 mL | 0.6999 mL |